New Allergy Therapies To Come Of Age In 2016
This article was originally published in Scrip
Executive Summary
2016 will be the year when researchers, allergy sufferers and investors will receive Phase III results about a potential cat allergy therapy, will find out if a merger between two allergy companies has produced an acquisitive sector leader – Stallergenes Greer PLC - and if new technologies, including a once-daily patch, are likely to benefit patients with food allergies to peanuts and dairy.